Nifty
Sensex
:
:
18111.50
60821.62
-66.60 (-0.37%)
-101.88 (-0.17%)

Pharmaceuticals & Drugs - Global

Rating :
51/99

BSE: 524404 | NSE: MARKSANS

67.20
21-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  67.80
  •  68.80
  •  66.60
  •  67.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  945870
  •  637.37
  •  97.60
  •  48.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,750.59
  • 10.92
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,557.04
  • 0.37%
  • 2.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.25%
  • 2.41%
  • 42.41%
  • FII
  • DII
  • Others
  • 2.64%
  • 0.34%
  • 3.95%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.49
  • 12.40
  • 11.23

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 59.48
  • 20.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 92.92
  • 45.59

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.98
  • 15.57
  • 12.39

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.61
  • 2.78
  • 2.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.14
  • 14.35
  • 7.91

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
348.96
331.15
5.38%
330.20
335.35
-1.54%
358.36
287.65
24.58%
356.47
256.40
39.03%
Expenses
271.63
261.13
4.02%
234.82
266.15
-11.77%
267.31
240.36
11.21%
273.31
222.83
22.65%
EBITDA
77.34
70.02
10.45%
95.37
69.20
37.82%
91.06
47.29
92.56%
83.16
33.57
147.72%
EBIDTM
22.16%
21.14%
28.88%
20.63%
25.41%
16.44%
23.33%
13.09%
Other Income
5.88
0.18
3,166.67%
6.01
0.03
19,933.33%
-3.17
0.03
-
3.67
7.88
-53.43%
Interest
0.97
1.55
-37.42%
2.83
2.04
38.73%
1.68
1.65
1.82%
1.93
2.81
-31.32%
Depreciation
7.47
7.25
3.03%
1.33
9.63
-86.19%
8.58
7.33
17.05%
18.99
4.98
281.33%
PBT
74.78
61.40
21.79%
97.22
57.56
68.90%
77.64
38.34
102.50%
65.90
33.66
95.78%
Tax
12.18
12.04
1.16%
17.73
14.82
19.64%
18.70
8.78
112.98%
15.16
7.69
97.14%
PAT
62.60
49.36
26.82%
79.50
42.74
86.01%
58.94
29.56
99.39%
50.73
25.97
95.34%
PATM
17.94%
14.91%
24.08%
12.74%
16.45%
10.28%
14.23%
10.13%
EPS
1.53
1.21
26.45%
1.94
1.04
86.54%
1.44
0.72
100.00%
1.24
0.63
96.83%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
1,393.99
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
796.69
630.00
438.42
355.55
Net Sales Growth
15.15%
21.33%
13.41%
9.57%
18.97%
-14.12%
12.13%
26.46%
43.70%
23.31%
 
Cost Of Goods Sold
594.15
595.05
567.83
498.01
523.13
458.74
509.69
445.44
367.93
252.86
212.92
Gross Profit
799.84
781.13
566.38
502.07
389.57
308.42
383.63
351.25
262.07
185.56
142.62
GP Margin
57.38%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
44.09%
41.60%
42.32%
40.11%
Total Expenditure
1,047.07
1,036.57
941.96
867.92
834.31
734.24
760.91
620.86
516.04
369.02
455.33
Power & Fuel Cost
-
16.42
14.38
14.34
11.83
13.27
12.58
9.72
7.80
6.12
4.89
% Of Sales
-
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
1.22%
1.24%
1.40%
1.38%
Employee Cost
-
197.32
168.42
159.07
147.75
149.70
122.42
72.61
66.44
55.91
45.70
% Of Sales
-
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
9.11%
10.55%
12.75%
12.85%
Manufacturing Exp.
-
127.47
113.32
77.14
59.90
47.34
50.44
37.59
30.11
9.85
8.76
% Of Sales
-
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
4.72%
4.78%
2.25%
2.46%
General & Admin Exp.
-
50.67
45.52
51.03
42.51
37.52
36.01
15.35
16.13
24.93
21.00
% Of Sales
-
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
1.93%
2.56%
5.69%
5.91%
Selling & Distn. Exp.
-
33.54
32.15
68.36
49.14
27.66
29.77
34.47
27.63
22.84
17.39
% Of Sales
-
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
4.33%
4.39%
5.21%
4.89%
Miscellaneous Exp.
-
16.10
0.34
-0.01
0.05
0.00
0.00
5.67
0.00
-3.49
17.39
% Of Sales
-
1.17%
0.03%
0.00%
0.01%
0%
0%
0.71%
0%
-0.80%
40.69%
EBITDA
346.93
339.61
192.25
132.15
78.38
32.92
132.42
175.83
113.96
69.40
-99.78
EBITDA Margin
24.89%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
22.07%
18.09%
15.83%
-28.06%
Other Income
12.39
6.69
0.33
4.62
8.47
18.85
12.72
12.23
7.28
4.40
2.05
Interest
7.41
7.99
8.75
9.66
10.22
6.78
10.16
16.05
19.13
14.60
53.58
Depreciation
36.37
36.15
26.66
22.80
26.84
30.09
28.13
16.13
15.69
15.65
23.70
PBT
315.54
302.16
157.17
104.31
49.80
14.90
106.85
155.88
86.41
43.55
-175.00
Tax
63.77
63.63
36.42
23.87
14.00
3.56
24.11
43.92
12.79
-5.28
1.08
Tax Rate
20.21%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
28.18%
14.80%
-12.12%
-0.62%
PAT
251.77
235.94
117.02
76.46
32.94
8.83
78.51
109.39
71.90
45.89
-178.84
PAT before Minority Interest
251.77
238.54
120.75
80.44
35.80
11.33
82.74
111.96
73.62
48.83
-176.08
Minority Interest
0.00
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
-2.57
-1.72
-2.94
-2.76
PAT Margin
18.06%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
13.73%
11.41%
10.47%
-50.30%
PAT Growth
70.54%
101.62%
53.05%
132.12%
273.05%
-88.75%
-28.23%
52.14%
56.68%
-
 
EPS
6.15
5.76
2.86
1.87
0.80
0.22
1.92
2.67
1.76
1.12
-4.37

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
886.49
636.01
542.48
470.86
433.43
454.32
379.76
142.18
86.48
-168.07
Share Capital
40.93
40.93
40.93
40.93
40.93
53.43
53.43
52.03
52.03
50.28
Total Reserves
845.56
595.08
501.55
429.93
392.50
400.89
326.33
90.15
34.45
-219.51
Non-Current Liabilities
23.70
24.15
17.14
15.64
16.07
-1.91
1.46
22.16
10.49
28.26
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
19.82
7.88
15.20
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
2.11
1.47
1.36
1.08
0.96
0.00
0.00
0.00
0.00
0.00
Current Liabilities
298.40
228.75
232.62
234.68
296.06
259.43
286.24
319.12
297.28
519.26
Trade Payables
168.66
110.33
106.07
77.83
161.78
118.98
107.02
83.18
56.06
58.62
Other Current Liabilities
79.12
58.86
20.90
10.08
0.71
0.68
39.88
96.58
108.73
336.39
Short Term Borrowings
18.74
18.84
99.91
117.41
109.71
87.89
82.19
105.54
113.79
113.92
Short Term Provisions
31.88
40.72
5.74
29.36
23.85
51.88
57.15
33.82
18.70
10.32
Total Liabilities
1,227.45
902.02
802.46
730.73
751.81
720.20
675.56
490.10
401.24
385.07
Net Block
309.36
302.72
269.73
279.38
266.98
269.65
165.90
145.65
156.12
165.35
Gross Block
607.09
565.39
506.26
495.35
456.49
429.47
297.78
261.70
256.88
250.51
Accumulated Depreciation
297.73
262.67
236.54
215.97
189.52
159.82
131.89
116.05
100.76
85.15
Non Current Assets
325.20
308.45
271.02
280.19
267.92
280.06
166.72
147.15
157.32
169.44
Capital Work in Progress
11.68
0.00
0.00
0.00
0.36
0.00
0.00
0.00
0.00
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
4.16
5.73
1.29
0.82
0.59
10.41
0.83
1.50
1.20
4.08
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
902.25
593.59
531.44
450.54
483.88
440.15
508.83
342.95
243.93
215.63
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
404.32
241.84
293.25
218.12
190.09
167.79
130.11
102.59
77.69
73.36
Sundry Debtors
271.38
243.35
176.60
176.91
247.58
217.29
183.45
169.61
131.31
112.77
Cash & Bank
212.29
93.73
33.54
39.88
25.16
35.30
185.27
46.95
15.88
22.39
Other Current Assets
14.27
11.26
28.06
15.63
21.05
19.76
10.01
23.80
19.04
7.11
Short Term Loans & Adv.
0.98
3.40
0.00
0.00
20.96
19.76
10.01
23.80
19.04
7.11
Net Current Assets
603.85
364.83
298.82
215.86
187.82
180.71
222.60
23.83
-53.36
-303.63
Total Assets
1,227.45
902.04
802.46
730.73
751.80
720.21
675.55
490.10
401.25
385.07

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
178.74
233.33
27.40
50.09
14.06
30.80
154.51
64.84
38.56
-62.30
PBT
302.16
157.17
104.31
49.80
14.90
106.85
109.40
71.91
45.88
-178.84
Adjustment
75.13
42.04
31.88
43.99
26.58
39.63
24.26
19.57
27.85
124.15
Changes in Working Capital
-150.03
59.12
-81.79
-36.23
-6.04
-88.14
20.27
-26.01
-35.18
-7.60
Cash after chg. in Working capital
227.27
258.33
54.40
57.56
35.44
58.34
153.94
65.47
38.56
-62.30
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
-0.89
-0.27
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-44.90
-59.58
-13.48
-38.81
-20.73
-123.01
-33.19
-4.49
-5.43
-3.25
Net Fixed Assets
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
-32.23
-2.62
-4.85
90.35
Net Investments
0.00
0.00
0.00
-1.78
-2.85
-163.82
0.00
0.00
-44.11
44.11
Others
-16.42
-35.71
9.59
-31.17
-6.39
62.82
-0.96
-1.87
43.53
-137.71
Cash from Financing Activity
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
16.99
-29.28
-39.64
57.02
Net Cash Inflow / Outflow
118.56
60.19
-6.86
14.67
-10.14
-149.96
138.32
31.07
-6.51
-8.53
Opening Cash & Equivalents
93.73
33.54
39.72
25.05
35.30
185.27
46.95
15.88
22.39
30.92
Closing Cash & Equivalent
212.29
93.73
32.85
39.72
25.16
35.30
185.27
46.95
15.88
22.39

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
21.66
15.54
13.25
11.50
10.59
10.79
8.97
3.34
1.89
-4.97
ROA
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
19.21%
16.52%
12.42%
-40.16%
ROE
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
45.15%
73.02%
0.00%
0.00%
ROCE
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
44.64%
38.30%
44.72%
-180.20%
Fixed Asset Turnover
2.35
2.12
2.00
1.92
1.73
2.46
2.85
2.43
1.73
1.20
Receivable days
68.26
67.57
64.51
84.88
110.59
81.87
80.88
87.17
101.60
108.63
Inventory Days
85.69
86.10
93.32
81.63
85.14
60.86
53.30
52.22
62.88
72.16
Payable days
44.06
45.09
38.48
55.10
65.56
54.58
56.06
48.85
59.34
68.51
Cash Conversion Cycle
109.89
108.58
119.35
111.40
130.17
88.15
78.13
90.54
105.14
112.28
Total Debt/Equity
0.02
0.03
0.18
0.25
0.25
0.19
0.23
1.12
1.88
-1.06
Interest Cover
38.83
18.97
11.80
5.87
3.20
11.52
10.72
5.52
3.98
-2.27

News Update:


  • Marksans Pharma gets approval from USFDA for Acetaminophen Extended-Release Tablets
    26th Aug 2021, 16:01 PM

    Acetaminophen Extended-Release Tablets are bioequivalent to the reference listed drug, Tylenol Extended-Release Tablets, 650 mg, of Johnson & Johnson Consumer Inc

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.